Obiettivo del trattamento della schizofrenia: RECOVERY FUNZIONALE

Size: px
Start display at page:

Download "Obiettivo del trattamento della schizofrenia: RECOVERY FUNZIONALE"

Transcription

1 Obiettivo del trattamento della schizofrenia: RECOVERY FUNZIONALE Autonomia abitativa Relazioni interpersonali Attività del tempo libero Lavoro/scuola Symptom remission alone is inadequate for a definition of recovery... Dimensions of improved psychosocial functioning must also be integral to a definition of recovery... these dimensions include work, school, family life, friends, recreation, and independent living. Liberman & Kopelowicz, Psychiatr Serv 2005

2 Schizofrenia e Recovery Meta-analisi di 50 studi Recovery: La persona deve mostrare un recupero sia sul piano clinico che su quello psicosociale. In almeno uno di questi piani il recupero deve avere una durata di almeno 2 anni. A proportion of schizophrenia patients have a favourable prognosis and have a good clinical and functional outcomes Systematic review of available data showed that 13.5% of patients met recovery criteria Jääskeläinen et al. Schizophr Bull 2013

3 NEUROCOGNITIVE FUNCTIONING IN SCHIZOPHRENIA Summary of results from meta-analytic studies presented in effect-size units Reichenberg, Dialogues Clin Neurosci 2010

4 Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia Verbal Memory Attention Speed of Processing Working Memory Verbal memory, speed of processing and working memory were three of the domains with the greatest impairments The pattern of results is in line with previous meta-analytic findings in antipsychotic treated patients The present meta-analysis confirms the existence of significant cognitive impairments at the early stage of the illness in the absence of antipsychotic medication Fatouros-Bergman et al, Schizophr Res 2014

5 The Italian Network for Research on Psychoses Study Degree of cognitive impairment in individual subjects with schizophrenia (N=921) SD below norms SD below norms in at least 2 domains SD below norms in at least 2 domains SD below norms in at least 2 domains Mucci et al, 2017

6

7 Baseline Follow-Up 7 anni VELOCITÀ DI PROCESSAZIONE ATTENZIONE MEMORIA VERBALE FUNZIONAMENTO GLOBALE PSICOSOCIALE SINTOMI NEGATIVI (Milev et al., Am J Psychiatry, 2005)

8 Neurocognitive constructs and functional outcome Neuropsychopharmacology: The Fifth Generation of Progress 2002

9 Negative Symptoms, Cognitive Impairment and Real-Life Functioning Mediating Variables Functional Outcome Domains Neuro- Cognition Social Cognition Negative symptoms Social Occupational Independent Living Rehabilitation Success Green and Horan, Current Directions 2010

10 Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment NS may, to a certain extent, channel the deleterious influence of other symptoms into poor functional outcome with which NS are strongly correlated

11

12

13

14 SEM - Modello Finale

15 The Italian Network for Research in Psychoses VARIABLES SHOWING SIGNIFICANT ASSOCIATION WITH FUNCTIONING TOTAL (direct+indirect) NEUROCOGNITIVE FUNCTIONING 0.30 PANSS DISORGANIZATION BNSS AVOLITION FUNCTIONAL CAPACITY 0.24 ENGAGEMENT WITH MENTAL HEALTH SERVICES SOCIAL COGNITION 0.17 PANSS POSITIVE INCENTIVES RESILIENCE 0.11 INTERNALIZED STIGMA Galderisi et al, World Psychiatry 2014

16

17 Is cognitive remediation effective? 0,5 0,4 0,3 0,2 0, participants 0 Effect size 0.45 Wykes et al., 2011

18

19 What differences really matter? Strategic approach produced a higher functional effect DP=0.34 (95% CI -0.11, 0.78); SC+=0.47 (95% CI 0.22, 0.73) Adjunctive psychiatric rehabilitation increases functional gains Rehab=0.59 (95% CI 0.30, 0.88); CRT only=0.28(95% CI -0.02, 0.58) 1 0,9 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0 SC+ Rehab DP+ Rehab Effect sizes when rehab provided

20

21

22 Continuous treatment Design CRT/SRT for 6 months CRT/SRT + post-therapy SRT Schizophrenia Research, 2017 Follow-up after 5 years Cognition stable over time in both groups BUT CRT/SRT + only produced stable functional improvement (Time by treatment effect F=11.48, p<0.001)

23

24

25 USE OF PSYCHIATRIC SERVICES BEFORE AND AFTER TREATMENT IN THE CR GROUP Variable Number of hospitalizations in acute unit per month (mean±sd) Days of hospitalizations in acute units per month (mean±sd) Number of admissions in rehabilitative facilities per month (mean±sd) Days of stay in rehabilitative facilities per month (mean±sd) Number of total outpatient interventions per month (mean±sd) Number of total rehabilitation interventions per month (mean±sd) Before treatment 12 months after treatment 36 months after treatment 60 months after treatment 0.070± ±0.064* 0.020±0.037** 0.012±0.022** 1.855± ±1.431** 0.456±0.881** 0.486±1.165** 0.048± ±0.047* 0.013±0.023** 0.030± ± ± ±3.708* 5.140± ± ±26.568** ±27.907* ± ± ±19.367** ± ± * p<0.05 (Wilcoxon Signed Rank test, comparisons performed versus parameters before treatment) * * p<0.01 (Wilcoxon Signed Rank test, comparisons performed versus parameters before treatment)

26

27 Addestramento alle abilità sociali Rimedio cognitivo Interventi psicosociali Inserimento lavorativo Psicoeducazione Motivazione estrinseca e intrinseca Benessere soggettivo Sintomi, funzioni cognitive, social cognition Funzionamento Relazioni interpersonali Cura di sé sociale Lavoro/ Scuola Qualità della vita Recovery funzionale Autonomia Farmacoterapia (efficace, tollerata, continuativa) MODELLO DI INTERVENTO INTEGRATO NELLA SCHIZOFRENIA

28 DEPRESSION AND COGNITION Vita et al., 2016

29 Cognitive domain Meta-analysis of cognitive deficits in 1st-episode MDD: pooled effect sizes by cognitive domain Std mean difference IV, random, 95% CI Std mean difference IV, random, 95% CI Cognitive flexibility 0.53 [0.23, 0.83] Verbal fluency 0.59 [0.10, 1.07] Attentional switching 0.22 [0.00, 0.44] Visual learning and memory 0.53 [-0.05, 1.11] Verbal learning and memory 0.13 [-0.18, 0.45] Working memory Attention Psychomotor speed 0.16 [-0.20, 0.51] 0.36 [0.13, 0.59] 0.48 [0.21, 0.75] MDD, major depressive disorder; CI, confidence interval Controls performing worse Patients performing worse Lee RS et al. J Affect Disord 2012;140:113-24

30 Cognitive symptoms are common in depression Cognitive symptoms during depressive episodes Proportion of time spent without cognitive symptoms Residual cognitive symptoms in between depressive episodes Proportion of time spent without cognitive symptoms 94% Proportion of time spent with cognitive symptoms a 44% Proportion of time spent with cognitive symptoms a a According to Diagnostic and Statistical Manual of Mental Disorders 4th Edition: diminished ability to think or concentrate, or indecisiveness Prospective study (n=267) assessed 12 times over 3 years Conradi HJ et al. Psychol Med 2011;41:

31

32

Faculty. Delivering and Measuring the Outcomes of Cognitive Remediation across Clinical Settings. Evidence Base for Cognitive Remediation Therapy

Faculty. Delivering and Measuring the Outcomes of Cognitive Remediation across Clinical Settings. Evidence Base for Cognitive Remediation Therapy Faculty Delivering and Measuring the Outcomes of Cognitive Remediation across Clinical Settings Philip D. Harvey, PhD Leonard M. Miller Professor University of Miami Miller School of Medicine Miami, Florida

More information

The implementation of cognitive remediation interventions in Campania

The implementation of cognitive remediation interventions in Campania Original article The implementation of cognitive remediation interventions in Campania JOURNAL OF PSYCHOPATHOLOGY 2018;24:98-103 D. Palumbo*, S. Patriarca*, A. Mucci, M. De Angelis, I. Di Crosta, G. Piegari,

More information

November 2014 MRC2.CORP.X.00004

November 2014 MRC2.CORP.X.00004 This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid consultant of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking

More information

I received help from Bosch Health Care

I received help from Bosch Health Care John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early

More information

Occupational Therapy for First Episode Psychosis

Occupational Therapy for First Episode Psychosis 2018 International OT Conference Occupational Therapy for First Episode Psychosis Ms. Yeung Sau Fong, Odelia Occupational Therapy Department Kwai Chung Hospital HKSAR Early intervention Stage specific

More information

Schizophrenia: New Concepts for Therapeutic Discovery

Schizophrenia: New Concepts for Therapeutic Discovery Schizophrenia: New Concepts for Therapeutic Discovery William T. Carpenter, M.D. Professor of Psychiatry and Pharmacology University of Maryland School of Medicine Department of Psychiatry Maryland Psychiatric

More information

Early Stages of Psychosis. Learning Objectives

Early Stages of Psychosis. Learning Objectives Early Stages of Psychosis Stephan Heckers, MD MSc Department of Psychiatry and Behavioral Sciences Vanderbilt University Learning Objectives Summarize the five domains of psychosis Describe how psychotic

More information

RESEARCH UPDATES: Improving Functioning In Schizophrenia?

RESEARCH UPDATES: Improving Functioning In Schizophrenia? RESEARCH UPDATES: Improving Functioning In Schizophrenia? Stephen R. Marder, MD Professor and Director, Section on Psychosis Semel Institute for Neuroscience and Human Behavior at UCLA Director, Mental

More information

The British Approach to Understanding and Treating Psychosis

The British Approach to Understanding and Treating Psychosis The British Approach to Understanding and Treating Psychosis Robin M Murray Professor of Psychiatric Research Department of Psychosis Studies Institute of Psychiatry robin.murray@kcl.ac.uk Which boy will

More information

REVIEW. Innov Clin Neurosci. 2017;14(11 12):54 58

REVIEW. Innov Clin Neurosci. 2017;14(11 12):54 58 Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors ABSTRACT The Positive and Negative Syndrome Scale

More information

Gli aspetti cognitivi nei rischi ed esordi psicotici. Nadia Magnani UF Salute Mentale Adulti Grosseto Azienda USL Toscana sud est

Gli aspetti cognitivi nei rischi ed esordi psicotici. Nadia Magnani UF Salute Mentale Adulti Grosseto Azienda USL Toscana sud est Gli aspetti cognitivi nei rischi ed esordi psicotici Nadia Magnani UF Salute Mentale Adulti Grosseto Azienda USL Toscana sud est Stati mentali a rischio ed esordi psicotici Interazione tra ambiente e vulnerabilità

More information

Executive functions in major depressive disorder

Executive functions in major depressive disorder m Original paper http://doi.org/10.4038/sljpsyc.v9i1.8169 Executive functions in major depressive disorder K Dhawan, CY Sudarshan, S Begum Abstract Background It is reported that executive functions are

More information

The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry

The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry Robin M Murray Department of Psychosis Studies Institute of Psychiatry King s College London robin.murray@kcl.ac.uk

More information

Early identification of neurobiological markers of remission. Michael Bodnar, PhD Ashok K. Malla, MD Martin Lepage, PhD

Early identification of neurobiological markers of remission. Michael Bodnar, PhD Ashok K. Malla, MD Martin Lepage, PhD Early identification of neurobiological markers of remission Michael Bodnar, PhD Ashok K. Malla, MD Martin Lepage, PhD Outline Why study remission? Defining remission Data collection Results neurocognition

More information

Outcomes in Schizophrenia Systematic Reviews

Outcomes in Schizophrenia Systematic Reviews Outcomes in Schizophrenia Systematic Reviews Jouko Miettunen Professor of Clinical Epidemiology Center for Life Course Epidemiology and Systems Medicine, University of Oulu, Finland This project is co-funded

More information

Vortioxetina: evidenze sui sintomi cognitivi della depressione. Umberto Albert

Vortioxetina: evidenze sui sintomi cognitivi della depressione. Umberto Albert Vortioxetina: evidenze sui sintomi cognitivi della depressione Umberto Albert Depression is a clinically heterogeneous disorder Sadness Anxiety Irritability Lack of enjoyment Suicidal ideation Hopelessness

More information

Ethical Research Comittee

Ethical Research Comittee How should we take care of Schizophrenia today? Dr Laurence LACOSTE Saint Louis Hospital, Paris, France Ethical Research Comittee 1 Introduction: Schizophrenia and Psychiatry In psychiatric hospitals,

More information

The Right Stuff Revisited: What Have We Learned About the Determinants of Daily Functioning in Schizophrenia?

The Right Stuff Revisited: What Have We Learned About the Determinants of Daily Functioning in Schizophrenia? Schizophrenia Bulletin doi:10.1093/schbul/sbv018 Schizophrenia Bulletin Advance Access published March 7, 2015 Invited Commentary The Right Stuff Revisited: What Have We Learned About the Determinants

More information

THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd

THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU

More information

Cognitive remediation therapy for schizophrenia: an update on efficacy and intervention(s)

Cognitive remediation therapy for schizophrenia: an update on efficacy and intervention(s) Cognitive remediation therapy for schizophrenia: an update on efficacy and intervention(s) Vyv Huddy* Prof. Til Wykes*, Clare Reeder* and Caroline Cellard** * Department of Psychology, Institute of Psychiatry,

More information

Method. NeuRA Schizophrenia and bipolar disorder April 2016

Method. NeuRA Schizophrenia and bipolar disorder April 2016 Introduction Schizophrenia is characterised by positive, negative and disorganised symptoms. Positive symptoms refer to experiences additional to what would be considered normal experience, such as hallucinations

More information

LO SCOMPENSO DI CUORE

LO SCOMPENSO DI CUORE I SEMINARI DEL VENTENNALE 9 MAGGIO 2008 LO SCOMPENSO DI CUORE Angelo Bianchetti Dipartimento Medicina e Riabilitazione Istituto Clinico S.Anna, Brescia Gruppo di Ricerca Geriatrica, Brescia Conclusions

More information

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,

More information

Psychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives

Psychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives Psychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives TANG Tze-Chun Department of psychiatry KMUH Pharmacotherapy alone or combination with psychotherapy?

More information

The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia

The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia RESEARCH REPORT The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia SILVANA GALDERISI 1,ALESSANDRO ROSSI 2,PAOLA

More information

Method. NeuRA Cholinesterase inhibitors August 2016

Method. NeuRA Cholinesterase inhibitors August 2016 Introduction A supplementary, or adjunctive, treatment is administered in conjunction with a patient s ongoing antipsychotic therapy. (ChEI), or anticholinesterase, have been proposed as an additional

More information

Admission Criteria Continued Stay Criteria Discharge Criteria. All of the following must be met: 1. Member continues to meet all admission criteria

Admission Criteria Continued Stay Criteria Discharge Criteria. All of the following must be met: 1. Member continues to meet all admission criteria CMS Local Coverage Determination (LCD) of Psychiatry and Psychology Services for Massachusetts, New York, and Rhode Island L33632 Outpatient Services Coverage Indications and Limitations Hospital outpatient

More information

INTRODUCTION TO MENTAL HEALTH. PH150 Fall 2013 Carol S. Aneshensel, Ph.D.

INTRODUCTION TO MENTAL HEALTH. PH150 Fall 2013 Carol S. Aneshensel, Ph.D. INTRODUCTION TO MENTAL HEALTH PH150 Fall 2013 Carol S. Aneshensel, Ph.D. Topics Subjective Experience: From the perspective of mentally ill persons Context Public attitudes toward the mentally ill Definition

More information

Setting ambitious goals for patients with depression with a focus on functional recovery

Setting ambitious goals for patients with depression with a focus on functional recovery Setting ambitious goals for patients with depression with a focus on functional recovery The role of the overlooked cognitive symptoms in the treatment of depression Dr Andreas Papadopoulos Locum Consultant

More information

POT WEED CHRONIC GREEN KUSH BUD HERB

POT WEED CHRONIC GREEN KUSH BUD HERB POT WEED CHRONIC GREEN KUSH BUD HERB WHAT MOTIVATES YOU TO USE POT?* AVOID USING CANNABIS RELAXES ME HELPS ME FIT IN HELPS ME FORGET MAKES ME FEEL HAPPY HELPS ME SLEEP CHANGES MY REALITY *Though there

More information

Cognitive Remediation Therapy (CRT)

Cognitive Remediation Therapy (CRT) Cognitive Remediation Therapy (CRT) Experiences of implementation in inpatient rehabilitation services Dr Ian-Mark Kevan (Consultant Clinical Psychologist) BPS PCMHF Event 24 th March 2017 - Stirling Plan

More information

Advances in Bipolar Disorder Treatment

Advances in Bipolar Disorder Treatment Advances in Bipolar Disorder Treatment Avid Science Chapter 1 Effects of Cognitive Remediation in Patients with Bipolar Disorder M Hajri 1*, Z Abbes 1, H Ben Yahia 1, F Charfi 2, S Halayem 1, S Othman

More information

Program Outline. DSM-5 Schizophrenia Spectrum and Psychotic Disorders: Knowing it Better and Improving Clinical Practice.

Program Outline. DSM-5 Schizophrenia Spectrum and Psychotic Disorders: Knowing it Better and Improving Clinical Practice. DSM-5 Spectrum and Disorders: Knowing it Better and Improving Clinical Practice Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Program Outline Changes

More information

Maree Reser Doctorate of Psychology (clinical) candidate Swinburne University of Technology

Maree Reser Doctorate of Psychology (clinical) candidate Swinburne University of Technology Maree Reser Doctorate of Psychology (clinical) candidate Swinburne University of Technology Currently recruiting people with a diagnosis of schizophrenia or schizoaffective disorder to participate in a

More information

Cognitive Deficits in Schizophrenia

Cognitive Deficits in Schizophrenia Curr Tran Geriatr Gerontol Rep (2012) 1:45 52 DOI 10.1007/s13670-012-0006-5 COGNITIVE FUNCTION AND AGING (DAVE MORGAN, SECTION EDITOR) Cognitive Deficits in Schizophrenia Deborah J. Kayman Marjorie F.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:

More information

Abstract: "Evidence-Based Psychotherapy for Schizophrenia: Past, Present, and Future (Intermediate)

Abstract: Evidence-Based Psychotherapy for Schizophrenia: Past, Present, and Future (Intermediate) Shaun M. Eack, PhD David E. Epperson Professor of Social Work and Professor of Psychiatry School of Social Work and Department of Psychiatry University of Pittsburgh Pittsburgh, PA Abstract: "Evidence-Based

More information

Early detection and intervention of psychosis

Early detection and intervention of psychosis Early detection and intervention of psychosis New Data Benno G. Schimmelmann University Hospital of Child and Adolescent Psychiatry Bern, Bern, Switzerland Early detection of psychosis Early Detection

More information

Fidelity and Outcomes in Community Care

Fidelity and Outcomes in Community Care Faculty Disclosure Alex Kopelowicz, MD Dr. Kopelowicz has listed no financial interest/arrangement that would be considered a conflict of interest. Fidelity and Outcomes in Community Care Alex Kopelowicz,

More information

Cognitive Impairment in AOD: Assessment and Treatment

Cognitive Impairment in AOD: Assessment and Treatment Cognitive Impairment in AOD: Assessment and Treatment A Presentation for the Addiction Leadership Day 23 rd November 2016 Dr Jamie Berry Clinical Neuropsychologist Advanced Neuropsychological Treatment

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psychosis and schizophrenia in children and young people: recognition and management 1.1 Short title Psychosis and schizophrenia

More information

LA VALUTAZIONE DI ESITO IN SALUTE MENTALE

LA VALUTAZIONE DI ESITO IN SALUTE MENTALE LA VALUTAZIONE DI ESITO IN SALUTE MENTALE Angelo Barbato Laboratorio di Epidemiologia e Psichiatria Sociale IRCCS Istituto Mario Negri Scuola di specializzazione in Psicoterapia IRIS Milano Bologna 27

More information

Neurocognition and Neuroimaging Correlates of Persistent Negative Symptoms. Cindy Hovington Dr. Martin Lepage

Neurocognition and Neuroimaging Correlates of Persistent Negative Symptoms. Cindy Hovington Dr. Martin Lepage Neurocognition and Neuroimaging Correlates of Persistent Negative Symptoms Cindy Hovington Dr. Martin Lepage NEGATIVE SYMPTOMS Anhedonia Loss of Pleasure Asociality Decreased Social Drive Avolition Lack

More information

Chronic Schizophrenia: Explorations In Theory And Treatment. By Lawrence et al. Appleby

Chronic Schizophrenia: Explorations In Theory And Treatment. By Lawrence et al. Appleby Chronic Schizophrenia: Explorations In Theory And Treatment. By Lawrence et al. Appleby If you are searching for a book by Lawrence et al. Appleby Chronic Schizophrenia: Explorations in Theory and Treatment.

More information

Cognitive Remediation Therapy. CIRCuiTS

Cognitive Remediation Therapy. CIRCuiTS Cognitive Remediation Therapy CIRCuiTS Outline What is CRT and CIRCuiTS? Aims of the course Cognitive impairment in schizophrenia What is impaired? Why try to improve thinking skills? Research findings

More information

Schizophrenia update for GPs. Prof Douglas Turkington.

Schizophrenia update for GPs. Prof Douglas Turkington. Schizophrenia update for GPs. Prof Douglas Turkington.. The Schizophrenias Bleuler vs Kraepelin Sensitivity Disorder Traumatic Psychosis Drug-induced Psychosis Anxiety Psychosis (Kingdon and Turkington,

More information

UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool

UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool December-18 UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool Facility Name: Primary Dx: Member Gender: Member Age: Reviewer Name: Date of Facility Review:

More information

CLINICAL EFFECTIVENESS

CLINICAL EFFECTIVENESS CLINICAL EFFECTIVENESS Faculty Dr Ashok Malla Dr Rahul Manchanda Dr Toba Oluboka Dr Thomas Raedler Dr Marc-André Roy Dr Phil Tibbo Dr Richard Williams Audience Question What do you think Clinical Effectiveness

More information

8/22/2016. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd)

8/22/2016. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd) Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 16 Schizophrenia Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties, but can be as

More information

We will look at the definition of Neuro-Rehabilitation as opposed to Palliative Care, What impairments patients have at diagnosis How good we are at

We will look at the definition of Neuro-Rehabilitation as opposed to Palliative Care, What impairments patients have at diagnosis How good we are at We will look at the definition of Neuro-Rehabilitation as opposed to Palliative Care, What impairments patients have at diagnosis How good we are at picking these up; What we need to do to change the system

More information

Psychosis and Schizophrenia in Children and Young People

Psychosis and Schizophrenia in Children and Young People Psychosis and Schizophrenia in Children and Young People Review Questions Section A: Recognition Scope 4.3.1(a) Chapter 5 At Risk section 1. In CYP, what are the specific behaviours and symptoms that are

More information

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain

More information

Contemporary Psychiatric-Mental Health Nursing. Features of Schizophrenia. Features of Schizophrenia - continued

Contemporary Psychiatric-Mental Health Nursing. Features of Schizophrenia. Features of Schizophrenia - continued Contemporary Psychiatric-Mental Health Nursing Chapter 16 Schizophrenia and Other Psychotic Disorders Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties,

More information

Community Services - Eligibility

Community Services - Eligibility Community Services - Eligibility In order for DMH to reimburse care, the individual must meet both financial and clinical eligibility criteria. These criteria are described in detail in the DMH provider

More information

Cognitive enhancement therapy in schizophrenia. Matcheri S Keshavan MD

Cognitive enhancement therapy in schizophrenia. Matcheri S Keshavan MD Cognitive enhancement therapy in schizophrenia Matcheri S Keshavan MD Harvard Medical School, Massachusetts Mental Health Center and Beth Israel Deaconess Medical Center NIMH MH 60902, 92440 and 105596;

More information

Cognitive remediation in Recent Onset Schizophrenia: Results of an effectiveness trial

Cognitive remediation in Recent Onset Schizophrenia: Results of an effectiveness trial The Brain Dynamics Centre www.brain-dynamics.net Westmead Hospital & University of Sydney Cognitive remediation in Recent Onset Schizophrenia: Results of an effectiveness trial Dr Anthony Harris University

More information

Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention

Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases

More information

Cognitive Impairment in Euthymic Bipolar Affective Disorder Patients

Cognitive Impairment in Euthymic Bipolar Affective Disorder Patients Internal Journal of Scientific and Research Publics, Volume 5, Issue 10, October 2015 1 Cognitive Impairment in Euthymic Bipolar Affective Disorder Patients Dr. Mohan Babu M *, Dr. Supriya Hegde Aroor

More information

Neurocognition and Schizophrenia

Neurocognition and Schizophrenia Neurocognition and Schizophrenia Presenter Dr Swapna MBBS DPM MD PG III Outline Concepts and Development of neurocognition Domains of neurocognition in schizophrenia Specific emphasis on intelligence pertinent

More information

Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com

Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic

More information

Cognitive Remediation Intervention for people with Schizophrenia and Schizoaffective disorder in the Cavan Rehabilitation Service

Cognitive Remediation Intervention for people with Schizophrenia and Schizoaffective disorder in the Cavan Rehabilitation Service Royal College of Psychiatrists The Douglas Bennett Prize Cognitive Remediation Intervention for people with Schizophrenia and Schizoaffective disorder in the Cavan Rehabilitation Service Nnamdi Nkire,

More information

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.

More information

6th International Conference on Early Psychosis

6th International Conference on Early Psychosis OR015. Story production in first episode psychosis: the role of verbal learning memory and verbal fluency HJ Stain,1 S Hodne,2 I Joa,2 JO Johannesen,2 BR Rund,3 W ten Velden Hegelstad,2 TK Larsen2 1Centre

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

Psychotic Disorders. Schizophrenia. Age Distribution of Onset 2/24/2009. Schizophrenia. Hallmark trait is psychosis

Psychotic Disorders. Schizophrenia. Age Distribution of Onset 2/24/2009. Schizophrenia. Hallmark trait is psychosis Psychotic Disorders Schizophrenia Schizophrenia Affects people from all walks of life Is about as prevalent as epilepsy Usually begins in late adolescence or early adulthood Hallmark trait is psychosis

More information

Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis

Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis Reviews and Overviews Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis Diana O. Perkins, M.D., M.P.H. Hongbin Gu, Ph.D.

More information

Metacognitive Remediation Therapy

Metacognitive Remediation Therapy Metacognitive Remediation Therapy Global Burden of Disease Study 2010 Illness/Injury Disability Weight Schizophrenia: Acute State 0.756 Multiple Sclerosis: Severe 0.707 Spinal Cord Lesion at Neck: Untreated

More information

A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder

A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder O Reilly et al. BMC Psychiatry (2019) 19:27 https://doi.org/10.1186/s12888-019-2018-6 RESEARCH ARTICLE A randomized controlled trial of cognitive remediation for a national cohort of forensic patients

More information

The current conceptualization of negative symptoms in schizophrenia

The current conceptualization of negative symptoms in schizophrenia SPECIAL ARTICLE The current conceptualization of negative symptoms in schizophrenia Stephen R. Marder 1, Silvana Galderisi 2 1 Desert Pacific Mental Illness Research, Education, and Clinical Center, Semel

More information

A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia

A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia Schizophrenia Bulletin vol. 36 no. 2 pp. 419 427, 2010 doi:10.1093/schbul/sbn102 Advance Access publication on August 20, 2008 A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia Marie

More information

Insight in Mental Illness:

Insight in Mental Illness: Insight in Mental Illness: Impact on Adverse Effects, Functional Outcome and Treatment Adherence Joseph F. Goldberg, M.D. Clinical Professor of Psychiatry Icahn School of Medicine at Mount Sinai New York,

More information

CLINICAL EFFECTIVENESS

CLINICAL EFFECTIVENESS CLINICAL EFFECTIVENESS Faculty Dr Ashok Malla Dr Rahul Manchanda Dr Toba Oluboka Dr Thomas Raedler Dr Marc-André Roy Dr Phil Tibbo Dr Richard Williams Audience Question What do you think Clinical Effectiveness

More information

Lambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School

Lambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication

More information

Nicotinic Agonists for Cognitive Deficits in Schizophrenia: A Case Report

Nicotinic Agonists for Cognitive Deficits in Schizophrenia: A Case Report Nicotinic Agonists for Cognitive Deficits in Schizophrenia: A Case Report Annette Kennedy, PsyD Seattle Inst of Biomedical & Clinical Research, Mental Illness Research Education & Clinical Center (MIRECC)

More information

June 2015 MRC2.CORP.D.00030

June 2015 MRC2.CORP.D.00030 This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional

More information

Cognition in Mental Disorders:

Cognition in Mental Disorders: Cognition in Mental Disorders: Impairments, Implications, and Opportunities for Treatment Christopher R. Bowie, Ph.D., C.Psych. Professor Psychology, Psychiatry, & Centre for Neuroscience Studies Queen

More information

Measure #106 (NQF 0103): Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity

Measure #106 (NQF 0103): Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity Measure #106 (NQF 0103): Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity 2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

SCHIZOPHRENIA PROFOUNDLY AFFECTS

SCHIZOPHRENIA PROFOUNDLY AFFECTS Psychiatry and Clinical Neurosciences 2017; 71: 301 308 doi:10.1111/pcn.12486 Regular Article Does improvement of cognitive functioning by cognitive remediation therapy effect work outcomes in severe mental

More information

SKILLS TRAINING IN SCHIZOPHRENIA TABLE 1. Baseline Characteristics of Subjects With Schizophrenia or Schizoaffective Disorder Randomly Assigned to Cli

SKILLS TRAINING IN SCHIZOPHRENIA TABLE 1. Baseline Characteristics of Subjects With Schizophrenia or Schizoaffective Disorder Randomly Assigned to Cli Article Supplementing Clinic-Based Skills Training With Manual- Based Community Support Sessions: Effects on Social Adjustment of Patients With Schizophrenia Shirley M. Glynn, Ph.D. Stephen R. Marder,

More information

Curriculum Vitae, Carmen Zegarra, M.D. Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX 78731

Curriculum Vitae, Carmen Zegarra, M.D. Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX 78731 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Carmen Zegarra, M.D. FutureSearch

More information

Concise Reference Cognitive Dysfunction in Schizophrenia Richard Keefe, Martin Lambert, Dieter Naber

Concise Reference Cognitive Dysfunction in Schizophrenia Richard Keefe, Martin Lambert, Dieter Naber Concise Reference Cognitive Dysfunction in Schizophrenia Richard Keefe, Martin Lambert, Dieter Naber Concise Reference Cognitive Dysfunction in Schizophrenia Extracted from Current Schizophrenia, Third

More information

Neurocognitive Graphs of Schizophrenia and Major Depression Based on Cognitive Features

Neurocognitive Graphs of Schizophrenia and Major Depression Based on Cognitive Features Supplementary Materials Neurocognitive Graphs of Schizophrenia and Major Depression Based on Cognitive Features Sugai Liang#, Roberto Vega#, Xiangzhen Kong, Wei Deng, Qiang Wang, Xiaohong Ma, Mingli Li,

More information

Barbara Pajk, M.N. University Psychiatric Clinic Ljubljana

Barbara Pajk, M.N. University Psychiatric Clinic Ljubljana Barbara Pajk, M.N. University Psychiatric Clinic Ljubljana Barcelona, 21.7.2015 Introduction Tobacco use is the leading preventable cause of death in patients with psychiatric illnesses. 1 Every year millions

More information

Department of Science of Health, University of L Aquila, Italy

Department of Science of Health, University of L Aquila, Italy New evidence in theory of mind deficits in subjects with chronic schizophrenia and first episode: correlation with symptoms, neurocognition and social function Nuove evidenze nei deficit di teoria della

More information

A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning?

A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning? Paquin et al. BMC Psychiatry 2014, 14:139 RESEARCH ARTICLE Open Access A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Psychosis and schizophrenia in adults: treatment and management Quality standard title:

More information

Medical Necessity Criteria

Medical Necessity Criteria SECTION 3: MEDICAL NECESSITY CRITERIA 3.0 Definition of Medical Necessity Medical necessity is the principal criteria by which the Fresno County Mental Health Plan (FCMHP) decides to accept and approve

More information

Lessons learnt in recent trials in negative symptoms

Lessons learnt in recent trials in negative symptoms Lessons learnt in recent trials in negative symptoms D. Umbricht, N. Schooler, D. Fraguas, A. Khan, A. Kott, D. Daniel, C. Arango ISCTM Paris, September 1st, 2017 ISCTM ~ ECNP Joint Conference 1 September

More information

BlueCare Tennessee Practice Guidance For the Treatment of Schizophrenia Kelly Askins, MD and Deborah Gatlin, MD 3/9/2015 Reviewed: February, 2017

BlueCare Tennessee Practice Guidance For the Treatment of Schizophrenia Kelly Askins, MD and Deborah Gatlin, MD 3/9/2015 Reviewed: February, 2017 1 Cameron Hill Circle Chattanooga, TN 37402-0001 bluecare.bcbst.com BlueCare Tennessee Practice Guidance For the Treatment of Schizophrenia Kelly Askins, MD and Deborah Gatlin, MD 3/9/2015 Reviewed: February,

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

VA Recovery Transformation & Local Recovery Coordinators

VA Recovery Transformation & Local Recovery Coordinators VA Recovery Transformation & Local Recovery Coordinators David Carroll, Ph.D. Director, Recovery Services Office of Mental Health Services Department of Veterans Affairs David.Carroll@va.gov April 27,

More information

Update on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University

Update on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University Update on First Psychotic Episodes in Childhood and Adolescence Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University Childhood-Onset Psychosis 8% of psychiatrically referred youth

More information

Clozapine: Does it work? Analysis of a 15 year experience

Clozapine: Does it work? Analysis of a 15 year experience Article ID: WMC002228 ISSN 2046-1690 Clozapine: Does it work? Analysis of a 15 year experience Corresponding Author: Dr. Ennio Piantato, Division Chief / Dept of Mental Health, Azienda Ospedaliera Nazionale,

More information

BGS Falls Severe mental illness, poor bone health and falls: The potential role for physical activity

BGS Falls Severe mental illness, poor bone health and falls: The potential role for physical activity Severe mental illness, poor bone health and falls: The potential role for physical activity Brendon Stubbs MCSP, PhD Head of Physiotherapy South London and Maudsley NHS Foundation Trust Post Doctoral Research

More information

4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue

4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University

More information

Role of Clozapine in Treatment-Resistant Schizophrenia

Role of Clozapine in Treatment-Resistant Schizophrenia Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant

More information

Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing

Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing Mental Health Exchange Group December 3, 2014 W Joy Maddigan, PhD RN Background One component [the quantitative

More information